Successful products must have compelling value stories for all key stakeholders: providers, regulatory agencies, HTA bodies, payers, and patients. IQVIA can help you carry this through from clinical development to successful market entry and product acceptance by demonstrating the unique value and outcomes your advances bring. We can connect with a wide range of stakeholders and suggest the best way to communicate your value message so that it's understood.
There’s a stronger scientific emphasis in commercialization now due to drug pipelines dominated by specialized medicines and complex therapies targeting smaller patient populations. IQVIA can help you
Pipelines are expanding. In biotherapeutics, up to eight new cell-based therapies, gene therapies or regenerative medicine therapies are expected to launch each year between 2019 and 2022.
New drugs are increasingly more specialized, and the path from molecule to market involves defining the added value for ever smaller groups of patients.
Medical science liaisons (MSLs) are a link between years of research and development and the doctors and opinion leaders who shape patient awareness. Typically, MSLs have built deep, practical scientific knowledge in specific therapeutic areas. This expertise, together with their network of relationships, positions them to credibly communicate complex scientific and medical data to doctors and key opinion leaders.
Understand how payers, providers, and patients define value, and accelerate market access for new and innovative products.
Discover proven strategies and insights refined over more than 5,000 launches around the world.
Get insights into payer decision making and evidence requirements to accelerate market access for your drug.
Deploy the right resources where and when needed, and help sales teams effectively engage with busy healthcare professionals.